News
HC Wainwright & Co. Reiterates Buy on Icecure Medical, Maintains $3 Price Target
16 Apr 24
News, Price Target, Reiteration, Analyst Ratings
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results; Data Submitted To FDA Requesting Marketing Authorization To Treat Early-Stage Breast Cancer
15 Apr 24
Biotech, News, FDA, General
HC Wainwright & Co. Reiterates Buy on Icecure Medical, Maintains $3 Price Target
4 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Icecure Medical Q4 EPS $(0.07), Inline, Sales $1.25M Beat $1.17M Estimate
3 Apr 24
Earnings, Earnings Beats, News
Icecure Medical FY EPS $(0.32), Inline, Sales $3.23M Beat $3.14M Estimate
3 Apr 24
Earnings, News
Earnings Scheduled For April 3, 2024
3 Apr 24
Earnings
Alliance Global Partners Maintains Buy on Icecure Medical, Raises Price Target to $2.9
20 Mar 24
News, Price Target, Analyst Ratings
IceCure Medical Reports Topline Results From ICE3 Cryoablation Breast Cancer Study
19 Mar 24
Biotech, News, General
HC Wainwright & Co. Reiterates Buy on Icecure Medical, Maintains $3 Price Target
5 Mar 24
News, Price Target, Reiteration, Analyst Ratings
IceCure's ProSense Alternative Treatment For Extra-Pelvis Endometriosis: Independent Study Presented At ECR 2024
4 Mar 24
Biotech, News, Events, General
Study Using IceCure's ProSense Treatment Results In 100% Tumor Reduction In Early-Stage Breast Cancer; Shares Spike Higher
26 Feb 24
Biotech, News, General
Press releases
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response
30 Apr 24
Small Cap, Opinion, Press Releases
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response
30 Apr 24
Small Cap, Opinion, Press Releases
New Standard of Care? IceCure Submits Final ICE3 Data To FDA, Minimally Invasive Cryoablation Shows Similar 5-year Recurrence Outcomes To Surgery With Hormone Therapy
29 Apr 24
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer
15 Apr 24
Small Cap, Press Releases
Game-Changing Tumor Freezing Technology Has The Potential To Offer Women First-Ever Minimally Invasive Alternative To Breast Lumpectomy Surgery
12 Apr 24
IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance
3 Apr 24
Earnings, Small Cap, Press Releases
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes
2 Apr 24
Small Cap, Press Releases
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024
27 Mar 24
Small Cap, Press Releases
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy
19 Mar 24
Small Cap, Press Releases
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes
12 Mar 24
Small Cap, Press Releases
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference
7 Mar 24
Small Cap, Press Releases
IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024
4 Mar 24
Press Releases
Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop
27 Feb 24
Press Releases
IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan
15 Feb 24
Press Releases